BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2026 6:52:00 AM | Browse: 0 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 125300
Country China
Received
2026-07-06 08:12
Peer-Review Started
2026-07-06 08:12
First Decision by Editorial Office Director
Return for Revision
2026-07-19 03:45
Revised
2026-08-01 10:09
Publication Fee Transferred
2026-08-11 00:04
Editorial Processing by Scientific Editor
2026-09-15 02:45
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2026-09-15 09:34
Articles in Press
2026-09-15 09:34
Edit the Manuscript by Language Editor
Typeset the Manuscript
2026-09-28 01:17
Publish the Manuscript Online
2026-11-19 06:52
ISSN 1948-5204 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Case Report
Article Title Durable disease control with multimodal treatment including fulzerasib, cetuximab and radiotherapy in locally advanced pancreatic cancer: A case report
Manuscript Source Unsolicited Manuscript
All Author List Huan Luo, Zheng-Long Zhai, Jian Xu, Xiang Li, Yi-Wen Chen and Xue-Li Bai
ORCID
Author(s) ORCID Number
Jian Xu http://orcid.org/0000-0001-8132-8988
Xiang Li http://orcid.org/0000-0002-5942-7282
Yi-Wen Chen http://orcid.org/0000-0003-4525-0954
Xue-Li Bai http://orcid.org/0000-0002-2934-0880
Funding Agency and Grant Number
Funding Agency Grant Number
Ling Yan Research and Development Program of Department of Zhejiang Province Science and Technology No. 2026C02A1105 and No. 2024C03167
Corresponding Author Yi-Wen Chen, Department of Hepatobiliary and Pancreatic Surgery, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. cherry0705@zju.edu.cn
Key Words KRAS G12C mutation; Pancreatic ductal adenocarcinoma; Fulzerasib; cetuximab; Targeted therapy; Precision oncology; Case report
Core Tip This report presents the first known clinical application of a multimodal regimen combining the KRAS G12C inhibitor fulzerasib, the epidermal growth factor receptor antibody cetuximab, and localized carbon-ion radiotherapy in locally advanced pancreatic cancer harboring a KRAS G12C mutation. The treatment yielded durable disease control, extending progression-free survival beyond 19 months with a manageable safety profile in an 81-year-old patient unfit for conventional chemotherapy. This novel precision approach highlights the potential of combining dual-pathway targeted therapy with heavy-ion radiotherapy for KRAS-mutated locally advanced pancreatic cancer.
Publish Date 2026-11-19 06:52
Citation

Luo H, Zhai ZL, Xu J, Li X, Chen YW, Bai XL. Durable disease control with multimodal treatment including fulzerasib, cetuximab and radiotherapy in locally advanced pancreatic cancer: A case report. World J Gastrointest Oncol 2026; 18(12): 125300

URL https://www.wjgnet.com/1948-5204/full/v18/i12/125300.htm
DOI https://doi.org/10.4251/wjgo.125300
Full Article (PDF) WJGO-18-125300-with-cover.pdf